Could pay for the change of name maybe
Isis Pharmaceuticals Earns $5m in Milestone Payment From GSK
2014-11-03 12:03:46.877 GMT
By Catherine Larkin
Nov. 3 (Bloomberg) -- Isis Pharma milestone payment tied to
designation of ISIS-GSK5 as development candidate; drug is
second under pact with Glaxo to treat ocular disease.
Link to Statement:NSN NEGPC63MMTC4 <GO>
Link to Company News:ISIS US <Equity> CN <GO>
Link to Company News:GSK LN <Equity> CN <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the editor responsible for this story:
Catherine Larkin at +1-312-443-5968 or
clarkin4@bloomberg.net
2014-11-03 12:03:46.877 GMT
By Catherine Larkin
Nov. 3 (Bloomberg) -- Isis Pharma milestone payment tied to
designation of ISIS-GSK5 as development candidate; drug is
second under pact with Glaxo to treat ocular disease.
Link to Statement:NSN NEGPC63MMTC4 <GO>
Link to Company News:ISIS US <Equity> CN <GO>
Link to Company News:GSK LN <Equity> CN <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the editor responsible for this story:
Catherine Larkin at +1-312-443-5968 or
clarkin4@bloomberg.net